Log In
Print
BCIQ
Print
Print this Print this
 

Xyntha, antihemophilic factor, moroctocog alfa (formerly ReFacto AF)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionRecombinant Factor VIII (rFVIII)
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationBleeding
Indication DetailsControl and prevent bleeding in patients with hemophilia; Treat and prevent bleeding in patients with hemophilia A
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today